Fagron Increases Share Capital Through Subscription Rights

Fagron, the leading global company active in pharmaceutical compounding, has announced a significant increase in its share capital through the exercise of subscription rights. The company has issued 43,920 new shares, bringing its total share capital to €507,764,714.08. This increase brings the total number of shares with voting rights to 73,817,024, which also represents the total number of voting rights.

The exercise of these subscription rights took place on 21 September 2026. The Belgian company, Fagron NV, is headquartered in Nazareth, Belgium, and operates from its head office in Rotterdam, The Netherlands. The company is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’.

The total number of subscription rights to subscribe to not yet issued shares with voting rights stands at 962,713. Fagron NV, a subsidiary of Fagron BV, manages the company’s operational activities from its Rotterdam office.

This increase in share capital is a significant step for Fagron, reflecting the company's continued growth and commitment to its business objectives. The exercise of subscription rights is a common practice in the financial sector, allowing companies to expand their share base and potentially attract new investors.

Fagron NV, based in Nazareth, Belgium, and listed on Euronext Brussels and Euronext Amsterdam, is a leading company in the pharmaceutical compounding industry. The company operates in more than 38 countries worldwide, delivering personalized medicine to hospitals, pharmacies, clinics, and patients.